Increased levels of interleukins 8 and 10 as findings of canine inflammatory mammary cancer

Veterinary Immunology and Immunopathology

Volumn 152, Issue 3-4, 2013, Pages 245-251

  de Andrés, Paloma Jimena ^a   Illera, Juan Carlos ^a   Cáceres, Sara ^a   Díez, Lucía ^a   Pérez Alenza, Maria Dolores ^a   Peña, Laura ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Animal model; Canine; IBC; Inflammatory breast cancer; Inflammatory mammary cancer; Interleukins

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST HYPERPLASIA; CONTROLLED STUDY; DOG; ENZYME IMMUNOASSAY; FEMALE; INFLAMMATORY BREAST CANCER; MAMMARY GLAND; NONHUMAN; ORGAN DONOR; PROTEIN BLOOD LEVEL; TISSUE HOMOGENATE;

ANIMALS; CASE-CONTROL STUDIES; DOG DISEASES; DOGS; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; INTERLEUKIN-10; INTERLEUKIN-8; INTERLEUKINS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; SPECIES SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; CANIS FAMILIARIS;

EID: 84875529863     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2012.12.010     Document Type: Article

References (61)

1. Angelo L.S., Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin. Cancer Res. 2007, 13:2825-2830.
2. Apte R.N., Krelin Y., Song X., Dotan S., Recih E., Elkabets M., Carmi Y., Dvorkin T., White R.M., Gayvoronsky L., Segal S., Voronov E. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur. J. Cancer 2006, 42:751-759.
3. Arias-Pulido H. Incidence of mouse mammary tumor virus-like variant sequences in inflammatory breast cancer. Third International Inflammatory Breast Cancer Conference 2012, 1-2.
4. Arihiro K., Oda H., Kaneko M., Inai K. Cytokines facilitate chemotactic motility of breast carcinoma cells. Breast Cancer 2000, 7:221-230.
5. Asgeirsson K.S., Olafsdottir K., Jonasson J.G., Ogmundsdottir H.M. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine 1998, 10:720-728.
6. Bachelot T., Ray-Coquard I., Menetrier-Caux C., Rastkha M., Duc A., Blay J.Y. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br. J. Cancer 2003, 88:1721-1726.
7. Benoy I.H., Salgado R., Van Dam P., Geboers K., Van Marck E., Scharpe S., Vermeulen P.B., Dirix L.Y. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 2004, 10:7157-7162.
8. Bieche I., Lerebours F., Tozlu S., Espie M., Marty M., Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin. Cancer Res. 2004, 10:6789-6795.
9. Clemente M., De Andrés P.J., Peña L., Pérez-Alenza M.D. Survival time of dogs with inflammatory mammary cancer treated with palliative therapy alone or palliative therapy plus chemotherapy. Vet. Rec. 2009, 165:78-81.
10. Clemente M., Pérez-Alenza M.D., Illera J.C., Peña L. Histological, immunohistological, and ultrastructural description of vasculogenic mimicry in canine mammary cancer. Vet. Pathol. 2010, 47:265-274.
11. Coico R., Sunshine G., Benjamini E. Immunology: A Short Course 2003, vol. xxv. Wiley-Liss, Hoboken, NJ, Chichester, 361 pp. 5th ed.
12. Charafe-Jauffret E., Mrad K., Intidhar Labidi S., Ben Hamida A., Ben Romdhane K., Ben Abdallah M., Ginestier C., Esterni B., Birnbaum D., Ben Ayed F., Xerri L., Viens P., Mezlini A., Jacquemier J. Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast 2007, 16:352-358.
13. Chavey C., Bibeau F., Gourgou-Bourgade S., Burlinchon S., Boissiere F., Laune D., Roques S., Lazennec G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 2007, 9:R15.
14. de M. Souza C.H., Toledo-Piza E., Amorin R., Barboza A., Tobias K.M. Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can. Vet. J. 2009, 50:506-510.
15. Derin D., Soydinc H.O., Guney N., Tas F., Camlica H., Duranyildiz D., Yasasever V., Topuz E. Serum IL-8 and IL-12 levels in breast cancer. Med. Oncol. 2007, 24:163-168.
16. Freund A., Chauveau C., Brouillet J.P., Lucas A., Lacroix M., Licznar A., Vignon F., Lazennec G. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003, 22:256-265.
17. Gelaleti G.B., Jardim B.V., Leonel C., Moschetta M.G., Zuccari D.A. Interleukin-8 as a prognostic serum marker in canine mammary gland neoplasias. Vet. Immunol. Immunopathol. 2012, 146:106-112.
18. Gonzalez-Angulo A.M., Hennessy B.T., Broglio K., Meric-Bernstam F., Cristofanilli M., Giordano S.H., Buchholz T.A., Sahin A., Singletary S.E., Buzdar A.U., Hortobagyi G.N. Trends for inflammatory breast cancer: is survival improving?. Oncologist 2007, 12:904-912.
19. Haagensen C.D. Inflammatory Carcinoma 1956, Saunders, Philadelphia.
20. Illera J.C., Pérez-Alenza M.D., Nieto A., Jimenez M.A., Silvan G., Dunner S., Peña L. Steroids and receptors in canine mammary cancer. Steroids 2006, 71:541-548.
21. Jaiyesimi I.A., Buzdar A.U., Hortobagyi G. Inflammatory breast cancer: a review. J. Clin. Oncol. 1992, 10:1014-1024.
22. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of tumor escape" phenotypes. Nat. Immunol. 2002, 3:999-1005.
23. Kim J.H., Yu C.H., Yhee J.Y., Im K.S., Sur J.H. Lymphocyte infiltration, expression of interleukin (IL)-1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours. J. Comp. Pathol. 2010, 142:177-186.
24. Knupfer H., Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res. Treat. 2007, 102:129-135.
25. Kobayashi H., Shirakawa K., Kawamoto S., Saga T., Sato N., Hiraga A., Watanabe I., Heike Y., Togashi K., Konishi J., Brechbiel M.W., Wakasugi H. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256). Cancer Res. 2002, 62:860-866.
26. Kozlowski L., Zakrzewska I., Tokajuk P., Wojtukiewicz M.Z. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz. Akad. Med. Bialymst. 2003, 48:82-84.
27. Lana S.E., Rutteman G.R., Withrow S.J. Tumors of the mammary gland. Withrow and MacEwen's Small Animal Clinical Oncology 2007, 619-636. Saunders Elsevier, St. Louis, Missouri. S.J. Withrow, D.M. Vail (Eds.).
28. Lee B.J., Tannenbaum E. Inflammatory carcinoma of the breast. Surg. Gynecol. Obstet. 1924, 39:580.
29. Levine P. Current epidemiologic studies: advances and obstacles. Third International Inflammatory Breast Cancer Conference 2012.
30. Levine P.H., Mesa-Tejada R., Keydar I., Tabbane F., Spiegelman S., Mourali N. Increased incidence of mouse mammary tumor virus-related antigen in Tunisian patients with breast cancer. Int. J. Cancer 1984, 33:305-308.
31. Lewis A.M., Varghese S., Xu H., Alexander H.R. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Transl. Med. 2006, 4:48.
32. Li J., Perrella M.A., Tsai J.C., Yet S.F., Hsieh C.M., Yoshizumi M., Patterson C., Endege W.O., Zhou F., Lee M.E. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J. Biol. Chem. 1995, 270:308-312.
33. Lin Y., Huang R., Chen L., Li S., Shi Q., Jordan C., Huang R.P. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int. J. Cancer 2004, 109:507-515.
34. Lyon D.E., McCain N.L., Walter J., Schubert C. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs. Res. 2008, 57:51-58.
35. Marconato L., Romanelli G., Stefanello D., Giacoboni C., Bonfanti U., Bettini G., Finotello R., Verganti S., Valenti P., Ciaramella L., Zini E. Prognostic factors for dogs with mammary inflammatory carcinoma: 43 cases (2003-2008). J. Am. Vet. Med. Assoc. 2009, 235:967-972.
36. Merendino R.A., Arena A., Capozza A.B., Chillemi S., Mesiti M. Serum levels of interleukin-10 in patients affected by breast cancer. Immunol. Lett. 1996, 53:59-60.
37. Mettler L., Salmassi A., Heyer M., Schmutzier A., Schollmeyer T., Jonat W. Perioperative levels of interleukin-1beta and interleukin-6 in women with breast cancer. Clin. Exp. Obstet. Gynecol. 2004, 31:20-22.
38. Millanta F., Caneschi V., Ressel L., Citi S., Poli A. Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma. J. Comp. Pathol. 2010, 142:36-42.
39. Misdorp W., Else R.W., Hellmen E., Lipscomb T.P. Histological Classification of Mammary Tumors of the Dog and the Cat 1999, World Human Organization VII.
40. Moore K.W., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T.R. Interleukin-10. Annu. Rev. Immunol. 1993, 11:165-190.
41. Papiernik M., do Carmo Leite-de-Moraes M., Pontoux C., Joret A.M., Rocha B., Penit C., Dy M. T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity. J. Immunol. 1997, 158:4642-4653.
42. Peña L., De Andrés P.J., Clemente M., Cuesta P., Pérez-Alenza M.D. Prognostic value of histological grading in noninflammatory canine mammary carcinomas in a prospective study with two-year follow-up: relationship with clinical and histological characteristics. Vet. Pathol. 2012, 10.1177/0300985812447830.
43. Peña L., Pérez-Alenza M.D., Rodríguez-Bertos A., Nieto A. Canine inflammatory mammary carcinoma: histopathology, immunohistochemistry and clinical implications of 21 cases. Breast Cancer Res. Treat. 2003, 78:141-148.
44. Pérez-Alenza M.D., Tabanera E., Peña L. Inflammatory mammary carcinoma in dogs: 33 cases (1995-1999). J. Am. Vet. Med. Assoc. 2001, 219:1110-1114.
45. Pogo B.G., Holland J.F., Levine P.H. Human mammary tumor virus in inflammatory breast cancer. Cancer 2010, 116:2741-2744.
46. Purohit A., Newman S.P., Reed M.J. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002, 4:65-69.
47. Queiroga F.L., Pérez-Alenza M.D., Silván G., Peña L., Lopes C., Illera J.C. Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance. Anticancer Res. 2005, 25:4269-4275.
48. Reed M.J., Coldham N.G., Patel S.R., Ghilchik M.W., James V.H. Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells. J. Endocrinol. 1992, 132:R5-R8.
49. Sánchez-Archidona A.R., Jimenez M.A., Pérez-Alenza D., Silván G., Illera J.C., Peña L., Dunner S. Steroid pathway and oestrone sulphate production in canine inflammatory mammary carcinoma. J. Steroid Biochem. Mol. Biol. 2007, 104:93-99.
50. Shirakawa K., Furuhata S., Watanabe I., Hayase H., Shimizu A., Ikarashi Y., Yoshida T., Terada M., Hashimoto D., Wakasugi H. Induction of vasculogenesis in breast cancer models. Br. J. Cancer 2002, 87:1454-1461.
51. Shirakawa K., Kobayashi H., Heike Y., Kawamoto S., Brechbiel M.W., Kasumi F., Iwanaga T., Konishi F., Terada M., Wakasugi H. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002, 62:560-566.
52. Shirakawa K., Kobayashi H., Sobajima J., Hashimoto D., Shimizu A., Wakasugi H. Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res. 2003, 5:136-139.
53. Shirakawa K., Tsuda H., Heike Y., Kato K., Asada R., Inomata M., Sasaki H., Kasumi F., Yoshimoto M., Iwanaga T., Konishi F., Terada M., Wakasugi H. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001, 61:445-451.
54. Shirakawa K., Wakasugi H., Heike Y., Watanabe I., Yamada S., Saito K., Konishi F. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int. J. Cancer 2002, 99:821-828.
55. Susaneck S.J., Allen T., Hoopes J., Withrow S.J., Macy D.W. Inflammatory mammary carcinoma in the dog. J. Am. Anim. Hosp. Assoc. 1983, 19:971-976.
56. Tavassoli F.A. Pathology of the Breast 1999, vol. XIV. McGraw-Hill, New York, 874 pp. 2nd ed.
57. Van Golen K.L., Wu Z.F., Qiao X.T., Bao L., Merajver S.D. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000, 2:418-425.
58. Verhasselt B., Van Damme J., van Larebeke N., Put W., Bracke M., De Potter C., Mareel M. Interleukin-1 is a motility factor for human breast carcinoma cells in vitro: additive effect with interleukin-6. Eur. J. Cell Biol. 1992, 59:449-457.
59. Wilson J., Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin. Cancer Biol. 2002, 12:113-120.
60. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
61. Zuccari D.A., Castro R., Gelaleti G.B., Mancini U.M. Interleukin-8 expression associated with canine mammary tumors. Genet. Mol. Res. 2011, 10:1522-1532.